TOKYO--(BUSINESS WIRE)--Shinkowa Pharmaceutical Co., Ltd. (Head office: Chuo Ward, Tokyo, Japan, Representative director: Megumi Tanaka) commercialized the world's first nutraceuticals and cosmetics containing β-nicotinamide mononucleotide (NMN), with an amazing purity degree of 99.8 %. We were the world’s first company to carry out human clinical research and, based on science, we have kept launching products steadily, being considered pioneers in the world of NMN bioventure, all the way from research to commercialization.
With a view to turn productive aging into a worldwide reality, we will continue to grow even further and reinforce NMN research, awareness of the effects of NMN and its commercialization.
We have conducted the world's first long-term oral intake of NMN (24 weeks) with the Graduate School of Medical and Dental Health Sciences, National University of Hiroshima, and the interim report of this study has confirmed the appearance of Sirtuin 1 (longevity gene 1) and the increase of many different growth hormones, especially melatonin.
In addition, in order to understand the mechanisms of action of NMN, the non-profit organization The Systems Biology Institute (SBI) (representative: Hiroaki Kitano) has carried out a study called Understanding the Intracellular Mechanism of NMN by Multi-Omics Analysis. Also, National University of Yamaguchi, Joint Faculty of Veterinary Medicine, has started the analysis of the mechanisms of anti-aging symptoms taking companion animals (dogs) as subjects to confirm the control of anti-aging factors. Lastly, we have inaugurated and run our in-house research laboratory in Tokyo, Japan, to further increase the scientific basis of NMN.
Awareness of the effects of NMN
Following the success of the event we organized in December 2018 in Tokyo (Japan), we held a lecture in Shanghai (China) on May 2, 2019.
Chaired by Dr. Hiroaki Kitano, representative of the non-profit
corporation The Systems Biology Institute (SBI), we could benefit from
lectures by Professor Shin-Ichiro Imai (Thinking about Health-
Realization of Productive Aging from the Vanguard of Aging and Lifespan)
and Doctor Yoichi Nabeshima (Recent Advances in Aging Research- New
Developments in Alzheimer's Research).
Now we would like to organize such events in many other countries.
- Professor Shin-Ichiro Imai: Washington University in St. Louis (Missouri), School of Medicine, Department of Developmental Biology/ Department of Medicine (joint)
- Doctor Yoichi Nabeshima: Director of Institute of Biomedical Research and Innovation Center, Professor Emeritus of Kyoto University, Project Fellow of Center for Research and Development Strategy (JST/CRDS)
We would like to mention that on June 13, the latest research paper by
Professor Shin-Ichiro Imai was published in Cell Metabolism.
For more information on the paper, click on the link below:
Title: Extracellular Vesicle-Contained eNAMPT Delays Aging and Extends Lifespan in Mice
For more information about Professor Shin-Ichiro Imai and his research, please click on the link below:
As a token of our gratitude for all those who have kept an eye on us, and with the intention to reach even further and let new customers try our products, we are launching a thank-you campaign to offer you special discounts for a limited time.
11:00 AM June 14, 2019 - 11:00 AM June 21, 2019 (Tokyo time)
10 % DISCOUNT ON ALL PRODUCTS (from unit price)
You can buy our products on the links below:
Rakuten Global Market
Mirai Lab Official Store
What is NMN (β-nicotinamide mononucleotide)?
NMN (β-nicotinamide mononucleotide) is a substance included in the vitamin B3 group, and it is present in all organisms. It is enzyme-based and it can be found in foods such as broccoli and edamame beans, but we cannot replenish our NMN body stock by simple oral ingest. NMN is produced in the body, and it is a coenzyme essential to sustain life.
NMN is converted to NAD+ and acts on the life support center of the hypothalamus, which in turn acts on skeletal muscle, viscera, cells, mitochondria, blood vessels, nerves and response proteins (signal substances) among others, all essential for sustaining life.
NMN is a precursor of NAD+. When NMN acts, it is transformed into NAD+, but even if NAD+ is ingested directly, we cannot obtain the same effects as with NMN. In fact, when NAD+ is ingested, most of it is broken up in the digestive tract.
In addition, direct administration of NAD+ into blood vessels starts a process in which glycogen phosphorylase catalyzes breakdown of glycogen into glucose-1-phosphate, and further into glucose-6-phosphate. Blood glucose level starts to decline (something similar occurs in diabetes.) NAD+ does not pass through the brain barrier, so we cannot expect the effects that we get when we ingest NMN.